Mr. Dilip Shanghvi, Managing Director of the Company said, “I would also like to welcome Mr. Vivek Chaand Sehgal who has joined us as an independent director as of today. Mr. Sehgal is a very successful entrepreneur and is the Chairman of Samvardhana Motherson Group and Motherson Sumi Systems Ltd. Under the leadership of Mr. Sehgal, Samvardhana Motherson Group has evolved into a US$ 9 billion leading full system solutions provider to the global automotive industry, starting with an initial equity capital of US$ 17 in 1977. I believe that Sun Pharma will benefit from his experience and guidance.” This was announced at the time of Q2 results were taken on record by the Board of Directors at a meeting held in Mumbai.
A challenging US generic pricing environment coupled with continued investments in building our global specialty business has impacted our Q2 performance. We expect our performance to gradually improve in the second half of this year, Mr. Sanghvi Said.